Patient-specific, Effective, and Rational Functional Connectivity Targeting for DBS in OCD
(PERFECT DBS Trial)
DD
Overseen byDarin D Dougherty, MD
Age: 18 - 65
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Massachusetts General Hospital
No Placebo Group
Approved in 3 Jurisdictions
Trial Summary
What is the purpose of this trial?
The study aims to improve patient-specific anatomical targeting of the Deep Brain Stimulation for the treatment of intractable OCD.
Research Team
DD
Darin D Dougherty, MD
Principal Investigator
Massachusetts General Hospital
Eligibility Criteria
Inclusion Criteria
Approved to be implanted with a DBS device for OCD.
OCD, diagnosed by Structured Clinical Interview for DSM-5 (SCID-5), judged of disabling severity with a Yale-Brown Obsessive Compulsive Scale (YBOCS) score of at least 28.
Persistence of severe symptoms and impairment for five or more years despite: i. at least three adequate (≥3 months at the maximum tolerated dose) serotonin transporter inhibitor trials (may use any serotonin or serotonin-norepinephrine inhibitors, but must include a trial of clomipramine) alone or in combination with ii. adequate behavior therapy (≥20 sessions of expert exposure and response prevention; At least 20 sessions of behavioral therapy must be attempted), and iii. augmentation of one of the selective SRIs with a neuroleptic or clonazepam.
See 3 more
Treatment Details
Interventions
- Deep Brain Stimulation (Procedure)
Deep Brain Stimulation is already approved in Canada for the following indications:
Approved in Canada as Deep Brain Stimulation for:
- Essential tremor
- Parkinson's disease
- Dystonia
- Obsessive-compulsive disorder
- Epilepsy
- Chronic pain
Find a Clinic Near You
Who Is Running the Clinical Trial?
Massachusetts General Hospital
Lead Sponsor
Trials
3,066
Recruited
13,430,000+
Dr. William Curry
Massachusetts General Hospital
Chief Medical Officer
MD from Harvard Medical School
Dr. Anne Klibanski
Massachusetts General Hospital
Chief Executive Officer since 2019
MD from Harvard Medical School